Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
A phase 3 trial of Ribociclib in HR-positive / HER2-negative breast cancer, run by Olema Pharmaceuticals, Inc., now recruiting.
Overview
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer is a phase 3 interventional study registered as NCT07085767 by Olema Pharmaceuticals, Inc., with 1000 participants planned, started 2025-11-03 and due to reach its primary completion in 2028-12. Interventions recorded: Palazestrant, Letrozole-matching placebo, Ribociclib, Letrozole and Palazestrant matching-placebo.
Similar pages
not linked directly; found by shared links- TrialOP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
Shares Olema Pharmaceuticals, HR-positive / HER2-negative breast cancer and the tag pipeline.
- TrialPhase IIIb Study of Ribociclib + ET in Early Breast Cancer
Shares Ribociclib, Advanced Accelerator Applications (Novartis) and the tag pipeline.
- TrialStudy to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.
Shares Advanced Accelerator Applications (Novartis), HR-positive / HER2-negative breast cancer and the tag pipeline.
- TrialStudy of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer
Shares Advanced Accelerator Applications (Novartis) and the tag pipeline.
- TrialRibociclib (LEE011) Rollover Study for Continued Access
Shares Advanced Accelerator Applications (Novartis) and the tag pipeline.
- TrialA Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer
Shares Advanced Accelerator Applications (Novartis) and the tag pipeline.
- TrialA Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC
Shares Advanced Accelerator Applications (Novartis) and the tag pipeline.
- TrialA Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Shares Advanced Accelerator Applications (Novartis) and the tag pipeline.